Xeris Biopharma Holdings, Inc. (XERS) Financial Analysis & Valuation | Quarter Chart

Xeris Biopharma Holdings, Inc. (XERS)

XERS
Price: $5.85
Fair Value: 🔒
🔒score
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis,... more
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializi... more
Description Shares
Market Cap$1.01BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOJohn Shannon
IPO Date2018-06-21CAGR0.93%
Employees394Websitewww.xerispharma.com
Div. YieldPayout Ratio
Buy Back Yield1484997.42%Total Yield1484997.42%
XERS chart loading...
Fundamentals Technicals
Enterprise Value$694.88MP/E Ratio-58.5
Forward P/E15.79PEG Ratio
P/S Ratio0.01P/B Ratio-0.01
P/CF Ratio-0.01P/FCF Ratio-0.01
EPS$-0.1EPS Growth 1Y-76.86%
EPS Growth 3Y-89.86%EPS Growth 5Y-96.66%
Revenue Growth 1Y42.05%Gross Margin0.81%
Operating Margin-0.04%Profit Margin-0.13%
ROE1.14%ROA-0.1%
ROCE-0.04%Current Ratio1.95
Quick Ratio1.24Cash Ratio0.62
Debt/Equity-13.32Interest Coverage-0.33
Altman Z Score0.41Piotroski Score4